Results 161 to 170 of about 2,166,352 (310)

The " tipping point" and health care innovations: advancing the adoption of beneficial technologies : Accelerating Quality Improvement in Health Care Strategies to Speed the Diffusion of Evidence-Based Innovations, a conference held in Washington, D.C., January 27-28, 2003

Molly Joel Coye, Wade M. Aubry, Wil Yu.Cover title."Convened by National Institute for Health Care Management Foundation, National Committee for Quality Health Care.""Sponsored by Agency for Healthcare Research and Quality, Centers for Disease Control ...
Coye, Molly Joel.
core  

Improving health care quality : a guide for patients and families.

, 2000
"October 2000."Shipping list no.: 2001-0087-P.Cover title.Mode of access ...
United States. Agency for Healthcare Research and Quality.
core  

Advancing Access to Quality LGBTQIA+ Health Care: Gender Discrimination, Socio-Cultural, and Mental Health Issues: A Mixed-Method Study. [PDF]

Int J Environ Res Public Health, 2023
Argyriadis A, Fradelos EC, Argyriadi A, Ziegler E, Kaba E.   +4 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Patient satisfaction of medical care in a public health center

, 1998
The aim of this study was to examine differences in the level of satisfaction with medical care at a public health center between patients receiving free-care compared to those paying out-of-pocket.
조우현
core  

Systems leadership for quality in health care: from principles to actions. [PDF]

Int J Qual Health Care
Saxena A, Dickson G, Engel C, Agarwal V, Ahmed Z, Armit K, Braithwaite J, Dickson S, Lachman P, Moffat-Bruce S, Shaikh U, Wiig S.   +11 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

From tokenism to youth leadership in child and adolescent mental health research

Public Health Reviews
Sophie Mae Harrington, Paul Louis Fiedler, Katerina Sidiroglou, Nadia Ahmed, Hannah Brunskill, Jennifer Hall, Ledia Lazëri, João Breda   +7 more
doaj   +1 more source

Assessment of the quality of health care in emergency departments of governing hospitals in the Gaza Strip: A nurse's perspective. [PDF]

SAGE Open Med
Ahmad Jenenah AD, Abu El-Kass S.
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source